Read more at MarketWatch.
Sage Therapeutics’ stock plunges as Parkinson’s drug trial disappoints
Date: |
Sort by
Filter
Date
Items per page
-
Cannabis stocks rally after report that DEA will reclassify drug as less dangerous
Cannabis stocks were up sharply on Tuesday on a report by the Associated Press that the U.S. Drug Enforcement Administration is poised to propose moving cannabis to a Schedule III controlled substance.MarketWatch - Business -
European Carmakers Disappoint in Sluggish Start to Year
Volkswagen, Stellantis and Mercedes-Benz each said revenue and earnings fell in the first quarter, but pointed to growing pains that will generate gains from new and upgraded models later this year.The Wall Street Journal - Business - Europe -
Starbucks Shares Plunge After Sales, Earnings Miss
Speeding up service and introducing new beverages are part of efforts to win back customers, executives say.The Wall Street Journal - World -
Starbucks Shares Plunge After Sales, Earnings Miss
Speeding up service and introducing new beverages are part of efforts to win back customers, executives say.The Wall Street Journal - Business -
Embiid: ‘Disappointing' that Knicks fans had heavy presence for Sixers' Game 4 loss
Joel Embiid described the strong contingent of Knicks fans at Wells Fargo Center for the Sixers' Game 4 defeat Sunday as “disappointing.”Yahoo Sports - Sports - NBA -
Biden Administration Aims to Reclassify Marijuana as Less Dangerous Drug
The move would reshape the multibillion-dollar industry.The Wall Street Journal - World - Joe Biden -
Biden administration plans to reclassify marijuana as lower-risk drug
Drug Enforcement Administration seeking to downgrade cannabis from top category to Schedule III, but still short of legalization. The US Drug Enforcement Administration will move to reclassify marijuana as a less dangerous drug, the Associated ...The Guardian - World - Joe Biden -
FTC Targets 'Junk' Patent Listings on Ozempic and Other Drugs
The antitrust cop says that the more than 300 patent listings stall generic competition, keeping prices high for diabetes drugs, inhalers and more.The Wall Street Journal - World -
Lottery bids for skilled-worker visas plunge in the US after changes aimed at fraud and abuse
Authorities say lottery bids for highly educated worker visas plunged nearly 40% this yearABC News - Tech -
Ex-attorney for Daniels and McDougal testifies in Trump trial
Attorney Keith Davidson, a key witness who represented Stormy Daniels and Karen McDougal, was questioned Tuesday by prosecutors about the negotiations that led to Daniels' tabloid deal and hush money payment during the Donald Trump criminal trial. ...CNN - Top stories - Donald Trump
More from MarketWatch
-
AMD boosts its outlook for AI revenue, but its stock still falls
AMD lifted its outlook for its MI300 AI accelerator product, which is now expected to drive upwards of $4 billion in revenue this year.MarketWatch - Business -
401(k) plans lack one benefit that would make a big difference in retirement
While the U.S. retirement system relies on employer-provided 401(k) plans to help most workers save and invest for their golden years, few of these plans help retirees avoid outliving their old-age savings.MarketWatch - Business -
Using debt to finance government spending is not a free lunch
Government debt can be a valuable tool — but it has consequences.MarketWatch - Business -
Starbucks’ stock sinks 9% as ‘cautious’ consumers, more headwinds hit profit, revenue
Starbucks reported fiscal second-quarter earnings late Tuesday that were wide off the mark.MarketWatch - Business -
Mario Gabelli reveals his market-beating secrets and offers some favorite stock picks
The veteran investor’s recipe: Find a good business with good management, buy the stock at a reasonable price and hold long-term.MarketWatch - Business